EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST

Laurent Peyrin-Biroulet iD, Séverine Vermeire iD, Geert D'Haens, Julian Panés iD, Axel Dignass iD, Fernando Magro iD, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie und 6 weitere

Alimentary Pharmacology & Therapeutics · 2024-01 · 59 (2) · 175-185

DOI: 10.1111/apt.17751 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 30.11.2023. Verfasst von Laurent Peyrin-Biroulet und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Lorraine, INSERM, NGERE, Nancy, France. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen-Cilag, Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

STARDUST, a phase 3b randomised trial, compared ustekinumab therapeutic strategies in patients with Crohn's disease (CD) using early endoscopic assessment and treat‐to‐target (T2T) versus standard of care (SoC).

Aim

To assess the efficacy of ustekinumab extended treatment in a long‐term extension (LTE) of up to 104 weeks with dosing adapted according to clinical, biomarker and endoscopy outcomes.

Methods

Adults with moderately‐to‐severely active CD received intravenous ustekinumab approximating 6 mg/kg at Week 0 and subcutaneous ustekinumab 90 mg at Week 8. At Week 16, 440 ≥70‐point responders were randomised to T2T or SoC and 323 entered the LTE. At Week 48, a unified, protocol‐defined ustekinumab dose frequency escalation/de‐escalation was applied based on achieving endoscopic remission and corticosteroid‐free clinical remission. Achieving corticosteroid‐free clinical remission and biomarker remission at consecutive visits determined ustekinumab dosing frequency. Dichotomous variables were analysed using non‐responder imputation.

Results

Among patients who entered the LTE, 7.7%, 48.6% and 43.7% received doses every 4, 8 and 12 weeks, respectively. Ustekinumab dose frequency was escalated in 23.5% and de‐escalated in 19.7%. Endoscopic response and remission rates were 28.9% and 10.73% (all randomised) and 39.3% and 14.6% (patients entering the LTE), respectively, at Week 104. Clinical remission a rates at week 104 were 50.2% (all randomised) and 68.4% (patients entering the LTE). There were no new safety signals.

Conclusion

STARDUST LTE is the first interventional ustekinumab efficacy study to show a favourable benefit–risk profile with preservation of clinical and endoscopic outcomes through Week 104 using flexible, algorithm‐driven dose adjustment including de‐escalation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseAdultHumansRemission InductionEndoscopy, GastrointestinalBiomarkersTreatment Outcome

Substanzen

UstekinumabBiomarkers

Autor:innen und Institutionen

  • University of Lorraine, INSERM, NGERE, Nancy, France.
  • Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Center, Neuilly sur Seine, France.
  • Department of Gastroenterology & Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
  • Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.

ORCID-Profile: Laurent Peyrin-Biroulet, Séverine Vermeire, Julian Panés, Axel Dignass, Fernando Magro, Marco Daperno, Alessandro Armuzzi, Silvio Danese

Förderung

  • Janssen-Cilag, Limited

Zitieren

APA

Peyrin-Biroulet, L., Vermeire, S., D'Haens, G., Panés, J., Dignass, A., Magro, F., Nazar, M., Le Bars, M., Lahaye, M., Ni, L., Bravatà, I., Lavie, F., Daperno, M., Lukáš, M., Armuzzi, A., Löwenberg, M., Gaya, D. R., & Danese, S. (2024). Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics, 59(2), 175-185. https://doi.org/10.1111/apt.17751

Vancouver

Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, et al. Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics. 2024;59(2):175-185. doi:10.1111/apt.17751

BibTeX
@article{PeyrinBiroulet2024,
  author = {Peyrin-Biroulet, Laurent and Vermeire, Séverine and D'Haens, Geert and Panés, Julian and Dignass, Axel and Magro, Fernando and Nazar, Maciej and Le Bars, Manuela and Lahaye, Marjolein and Ni, Lioudmila and Bravatà, Ivana and Lavie, Frederic and Daperno, Marco and Lukáš, Milan and Armuzzi, Alessandro and Löwenberg, Mark and Gaya, Daniel R and Danese, Silvio},
  title = {Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {2},
  pages = {175--185},
  doi = {10.1111/apt.17751}
}
Kostenlos starten →